{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T07:40:06Z","timestamp":1782546006854,"version":"3.54.5"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Progressive glioblastoma (GBM) is a malignancy with extremely poor prognosis. Chemotherapy is one of the approved systemic treatment modalities. The aim of this study is to assess the cost-effectiveness of using bevacizumab (BEV) in combination with lomustine (LOM) regimen for the treatment of progressive glioblastoma in China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The estimation results are derived from a multicenter randomized phase III trial, which demonstrated improved survival in GBM patients receiving BEV+LOM combination therapy. To calculate the incremental cost-effectiveness ratio (ICER) from the perspective of Chinese society, a Markov model was established. Univariate deterministic analysis and probabilistic sensitivity analysis were employed to address the uncertainties within the model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared to LOM monotherapy, the total treatment cost for BEV+LOM combination therapy increased from $2,646.70 to $23,650.98. The health-adjusted life years (QALYs) for BEV+LOM combination therapy increased from 0.26 QALYs to 0.51 QALYs, representing an increment of 0.25 QALYs. The incremental cost-effectiveness ratio (ICER) was $84,071.12. The cost-effectiveness curve indicates that within the willingness-to-pay (WTP) range of $35,906 per QALY, BEV+LOM combination therapy is not a cost-effective treatment option for unresectable malignant pleural mesothelioma patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Taken as a whole, the findings of this study suggest that, from the perspective of payers in China, BEV+LOM combination therapy as a first-line treatment for GBM is not a cost-effective option. However, considering the survival advantages this regimen may offer for this rare disease, it may still be one of the clinical treatment options for this patient population.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2024.1410355","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T09:19:21Z","timestamp":1717060761000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost-effectiveness analysis of bevacizumab combined with lomustine in the treatment of progressive glioblastoma using a Markov model simulation analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Zhaoyan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"B1","unstructured":"National Comprehensive Cancer Network"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/S1470-2045(17)30194-8","article-title":"European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2009","journal-title":"J Clin Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"181s","DOI":"10.1200\/jco.2010.28.15_suppl.2008","article-title":"Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study","volume":"28","author":"Cloughesy","year":"2010","journal-title":"J Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e2326910","DOI":"10.1001\/jamanetworkopen.2023.26910","article-title":"Prevalence of use of potentially inappropriate medications among older adults worldwide: a systematic review and meta-analysis","volume":"6","author":"Tian","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e28732","DOI":"10.1002\/jmv.28732","article-title":"Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: a systematic review and meta-analysis","volume":"95","author":"Tian","year":"2023","journal-title":"J Med Virol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"106870","DOI":"10.1016\/j.ijantimicag.2023.106870","article-title":"Efficacy and safety of molnupiravir treatment for COVID-19: a systematic review and meta-analysis of randomized controlled trials","volume":"62","author":"Tian","year":"2023","journal-title":"Int J Antimicrob Agents."},{"key":"B12","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.clinthera.2008.02.013","article-title":"Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland","volume":"30","author":"Purmonen","year":"2008","journal-title":"Clin Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/0272989X9401400107","article-title":"Determining transition probabilities: confusion and suggestions","volume":"14","author":"Miller","year":"1994","journal-title":"Med Decis Making."},{"key":"B14","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e34588","DOI":"10.1371\/journal.pone.0034588","article-title":"Subgroup economic analysis for glioblastoma in a health resource-limited setting","volume":"7","author":"Wu","year":"2012","journal-title":"PLoS ONE."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vhri.2020.07.580","article-title":"Current development and practice of pharmacoeconomic evaluation guidelines for universal health coverage in China","volume":"24","author":"Yue","year":"2021","journal-title":"Value Health Reg Issues"},{"key":"B17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/phar.1870","article-title":"Cost-effectiveness analysis of second-line chemotherapy agents for advanced gastric cancer","volume":"37","author":"Lam","year":"2017","journal-title":"Pharmacotherapy."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1410355\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T09:19:27Z","timestamp":1717060767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1410355\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":17,"alternative-id":["10.3389\/fpubh.2024.1410355"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2024.1410355","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]},"article-number":"1410355"}}